A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients.
Rita De Sanctis,Rita De Sanctis,Elisa Agostinetto,Giovanna Masci,Emanuela Ferraro,Agnese Losurdo,Alessandro Viganò,Lidija Antunovic,Monica Zuradelli,Rosalba Torrisi,Armando Santoro +10 more
TL;DR: Activity and safety profiles of eribulin in a real-world population of metastatic breast cancer patients were consistent with literature data and DFA could be a promising tool to discriminate responses to erIBulin among MBC patients.
Journal ArticleDOI
Metiv-HCC: A phase III clinical trial evaluating tivantinib (ARQ 197), a MET inhibitor, versus placebo as second-line in patients (pts) with MET-high inoperable hepatocellular carcinoma (HCC).
Armando Santoro,Camillo Porta,Lorenza Rimassa,Ivan Borbath,Bruno Daniele,Richard S. Finn,Jean-Luc Raoul,Lawrence H. Schwartz,Aiwu Ruth He,Jörg Trojan,Markus Peck-Radosavljevic,Giovanni Abbadessa,Terri Goldberg,Jordi Bruix +13 more
TL;DR: Enrollment for this phase III clinical trial has begun and targets HCC patients with high tumor MET expression at immunohistochemistry as the target population for tivantinib in second line.
Journal ArticleDOI
Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis.
Pierina Navarria,Federico Pessina,Luca Cozzi,Stefano Tomatis,Giacomo Reggiori,Matteo Simonelli,Armando Santoro,Elena Clerici,Ciro Franzese,Giulio Carta,Marco Conti Nibali,Lorenzo Bello,Marta Scorsetti +12 more
TL;DR: HFRT has proven to be feasible and effective, with limited morbidity, for selected elderly and frail patients with newly diagnosed glioblastoma, and in selected patients, who need more aggressive treatment.
Journal ArticleDOI
Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy: A prospective evaluation of a case series and review of the literature.
Fiorenza De Rose,Antonella Fogliata,Davide Franceschini,Cristina Iftode,Pierina Navarria,Tiziana Comito,Ciro Franzese,Bethania Fernandes,Giovanna Masci,Rosalba Torrisi,Corrado Tinterri,Alberto Testori,Armando Santoro,Marta Scorsetti +13 more
TL;DR: Hypofractionated VMAT-SIB in patients who had undergone adjuvant systemic therapy was safe and well tolerated in terms of acute and early late settings and cosmesis and confirmed the results of other studies published on the association of hypofractionation and chemotherapy or concomitant boost.
Journal ArticleDOI
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Consuelo Buttigliero,Frances A. Shepherd,Fabrice Barlesi,Brian Schwartz,Sergey Orlov,Adolfo Favaretto,Armando Santoro,Vera Hirsh,Rodryg Ramlau,Adele R. Blackler,Joanna Roder,David R. Spigel,Silvia Novello,Wallace Akerley,Giorgio V. Scagliotti +14 more
TL;DR: VeriStrat showed a prognostic role within Eastern Cooperative Oncology Group (ECOG) performance score (PS) categories and regardless of treatment arm and EGFR status, suggesting that Veri Strat could be used to identify EGFR mutation-positive patients who will have a poor response to EGFR tyrosine kinase inhibitors.